PA8518301A1 - S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares - Google Patents
S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y ocularesInfo
- Publication number
- PA8518301A1 PA8518301A1 PA20018518301A PA8518301A PA8518301A1 PA 8518301 A1 PA8518301 A1 PA 8518301A1 PA 20018518301 A PA20018518301 A PA 20018518301A PA 8518301 A PA8518301 A PA 8518301A PA 8518301 A1 PA8518301 A1 PA 8518301A1
- Authority
- PA
- Panama
- Prior art keywords
- disorders
- disorder
- treatment
- anxiety
- psychotic
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 229960000607 ziprasidone Drugs 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- NHUDBVVEHOSVCD-UHFFFAOYSA-N 6-chloro-5-[2-[4-(2-methylsulfanylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound CSC1=CC=CC=C1C(=N)N1CCN(CCC=2C(=CC=3NC(=O)CC=3C=2)Cl)CC1 NHUDBVVEHOSVCD-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000027691 Conduct disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002996 emotional effect Effects 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ESTA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN S-METIL-DIHIDRO-ZIPRASIDONA Y AL USO DE DICHO COMPUESTO Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA EL TRATAMIENTO DE TRASTORNOS PSIQUIATRICOS Y OCULARES. DE UNA MANERA MAS ESPECIFICA, SE REFIERE AL USO DE DICHO COMPUESTO Y DE SUS SALES FARMACEUTICAMENTE ACEPTABLES PARA EL TRATAMIENTO DE UN TRASTORNO O AFECCION SELECCIONADO DE: ESQUIZOFRENIA, TRASTORNOS DE ANSIEDAD COMO EL TRASTORNO DE ANSIEDAD GENERALIZADA, TRASTORNO DE PANICO, TRASTORNO DE ESTRES POSTRAUMATICO Y FOBIAS (POR EJEMPLO, FOBIA SOCIAL, AGORAFOBIA, ETC.); EPISODIOS PSICOTICOS DE ANSIEDAD: ANSIEDAD, AGITACION, AGRESIVIDAD EXCESIVA, TENSION, O RETAIMIENTO SOCIAL O EMOCIONAL ASOCIADO CON PSICOSIS; TRASTORNOS DEL ESTADO DE ANIMO PSICOTICOS COMO EL TRASTORNO DEPRESIVO MAYOR GRAVE; TRASTORNOS DEL ESTADO DE ANIMO ASOCIADOS CON TRASTORNOS PSICOTICOS COMO LA MANIA AGUDA Y LA DEPRESION ASOCIADAS CON TRASTORNOS BIPOLARES, Y TRASTORNOS DEL ESTADO DE ANIMO ASOCIADOS CON ESQUIZOFRENIA; DESVIACIONES DEL COMPORTAMIENTO ASOCIADAS CON RETRASO MENTAL, TRASTORNOS DE AUTISMO Y TRASTORNOS DE LA CONDUCTA; DEMENCIAS COMO LAS DEMENCIAS ASOCIADAS CON LA ENFERMEDAD DE ALZHEIMER; DISCINESIAS INDUCIDAS POR DROGAS Y DE BASE NEURODEGENERATIVA; TRASTORNO OBSESIVO COMPULSIVO; SINDROME DE TOURETTE; GLAUCOMA; Y RETINOPATIA ISQUEMICA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20913600P | 2000-06-02 | 2000-06-02 | |
| US21217200P | 2000-06-16 | 2000-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8518301A1 true PA8518301A1 (es) | 2002-09-17 |
Family
ID=26903852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20018518301A PA8518301A1 (es) | 2000-06-02 | 2001-06-01 | S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares |
Country Status (44)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003296991A1 (en) | 2002-12-13 | 2004-07-09 | Regents Of The University Of Minnesota | Scleral depressor |
| US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
| JP2012174228A (ja) * | 2011-02-24 | 2012-09-10 | Kyocera Corp | プログラム保護装置および通信装置 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
| US9981041B2 (en) * | 2016-08-23 | 2018-05-29 | Ira Jason Salzman | Ophthalmic lubricating spray |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| KR100333214B1 (ko) * | 1996-05-07 | 2002-06-20 | 디. 제이. 우드, 스피겔 알렌 제이 | 5-(2-(4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐)에틸)-6-클로로-1,3-디하이드로-2(1에이치)인돌-2-온(지프라시돈)의메실레이트트리하이드레이트염,이의제조방법및도파민디2길항물질로서의이의용도 |
| PT985414E (pt) * | 1998-05-26 | 2004-01-30 | Pfizer Prod Inc | Metodo de tratamento de glaucoma e retinopatia isquemica |
| CA2363942A1 (en) * | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
-
2001
- 2001-05-28 EP EP01932011A patent/EP1286672B1/en not_active Expired - Lifetime
- 2001-05-28 DE DE60124093T patent/DE60124093D1/de not_active Expired - Lifetime
- 2001-05-28 IL IL15278201A patent/IL152782A0/xx active IP Right Grant
- 2001-05-28 JP JP2001587771A patent/JP2003534381A/ja not_active Withdrawn
- 2001-05-28 GE GE4972A patent/GEP20053512B/en unknown
- 2001-05-28 CN CN01810620A patent/CN1431901A/zh active Pending
- 2001-05-28 PL PL01365576A patent/PL365576A1/xx unknown
- 2001-05-28 EP EP06116051A patent/EP1698338B1/en not_active Expired - Lifetime
- 2001-05-28 UA UA2002119557A patent/UA79425C2/uk unknown
- 2001-05-28 CZ CZ20023860A patent/CZ20023860A3/cs unknown
- 2001-05-28 NZ NZ551012A patent/NZ551012A/en unknown
- 2001-05-28 BR BR0111271-6A patent/BR0111271A/pt not_active Application Discontinuation
- 2001-05-28 KR KR1020027016364A patent/KR20030007824A/ko not_active Application Discontinuation
- 2001-05-28 DE DE60133596T patent/DE60133596D1/de not_active Expired - Lifetime
- 2001-05-28 SI SI200130681T patent/SI1468686T1/sl unknown
- 2001-05-28 YU YU90702A patent/YU90702A/sh unknown
- 2001-05-28 AT AT01932011T patent/ATE343387T1/de not_active IP Right Cessation
- 2001-05-28 ES ES04013380T patent/ES2277170T3/es not_active Expired - Lifetime
- 2001-05-28 AT AT06116051T patent/ATE391507T1/de not_active IP Right Cessation
- 2001-05-28 PT PT06116051T patent/PT1698338E/pt unknown
- 2001-05-28 AT AT04013380T patent/ATE345818T1/de not_active IP Right Cessation
- 2001-05-28 EE EEP200200670A patent/EE200200670A/xx unknown
- 2001-05-28 PT PT04013380T patent/PT1468686E/pt unknown
- 2001-05-28 EP EP04013380A patent/EP1468686B1/en not_active Expired - Lifetime
- 2001-05-28 OA OA1200200349A patent/OA12267A/en unknown
- 2001-05-28 AU AU2001258690A patent/AU2001258690A1/en not_active Abandoned
- 2001-05-28 HU HU0301747A patent/HUP0301747A2/hu unknown
- 2001-05-28 MX MXPA02011862A patent/MXPA02011862A/es active IP Right Grant
- 2001-05-28 DE DE60124791T patent/DE60124791T2/de not_active Expired - Fee Related
- 2001-05-28 DK DK04013380T patent/DK1468686T3/da active
- 2001-05-28 CA CA002410618A patent/CA2410618A1/en not_active Abandoned
- 2001-05-28 SK SK1662-2002A patent/SK16622002A3/sk not_active Application Discontinuation
- 2001-05-28 EA EA200201168A patent/EA007068B1/ru not_active IP Right Cessation
- 2001-05-28 WO PCT/IB2001/000933 patent/WO2001091756A2/en active IP Right Grant
- 2001-05-31 AP APAP/P/2001/002180A patent/AP1831A/en active
- 2001-05-31 UY UY26742A patent/UY26742A1/es not_active Application Discontinuation
- 2001-05-31 AP AP2005003272A patent/AP1747A/xx active
- 2001-05-31 DO DO2001000181A patent/DOP2001000181A/es unknown
- 2001-05-31 PE PE2001000504A patent/PE20011329A1/es not_active Application Discontinuation
- 2001-05-31 HN HN2001000119A patent/HN2001000119A/es unknown
- 2001-06-01 SV SV2001000473A patent/SV2002000473A/es not_active Application Discontinuation
- 2001-06-01 PA PA20018518301A patent/PA8518301A1/es unknown
- 2001-06-01 AR ARP010102641A patent/AR028937A1/es unknown
- 2001-06-04 US US09/873,973 patent/US20060287336A1/en not_active Abandoned
-
2002
- 2002-11-11 IL IL152782A patent/IL152782A/en not_active IP Right Cessation
- 2002-11-12 BG BG107267A patent/BG107267A/bg unknown
- 2002-11-14 IS IS6619A patent/IS6619A/is unknown
- 2002-11-28 ZA ZA200209665A patent/ZA200209665B/en unknown
- 2002-11-29 NO NO20025760A patent/NO325077B1/no unknown
- 2002-11-29 MA MA26927A patent/MA26908A1/fr unknown
- 2002-11-29 EC EC2002004369A patent/ECSP024369A/es unknown
- 2002-12-02 HR HR20020953A patent/HRP20020953A2/hr not_active Application Discontinuation
-
2007
- 2007-02-08 CY CY20071100161T patent/CY1105992T1/el unknown
- 2007-11-14 JP JP2007296039A patent/JP2008056700A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR11095A (es) | Compuestos amino-heterociclicos | |
| CR7785A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| DE60239931D1 (de) | Kombinationstherapie | |
| PA8587101A1 (es) | Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos | |
| GT200500098A (es) | Nuevos compuestos | |
| UY32391A (es) | Compuestos amino-heterocíclicos | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| DOP2002000438A (es) | Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| DK1238676T3 (da) | Kombination af en serotoningenoptaghæmmer og et atypisk antipsykotikum til anvendelse ved depression, obsessiv-kompulsiv lidelse og psykoser | |
| AR032086A1 (es) | Combinaciones de farmacos | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| UY28400A1 (es) | Metabolito | |
| UY29924A1 (es) | Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables | |
| UY31346A1 (es) | Compuestos que tienen actividad en el receptor m1 y sus usos en medicina | |
| PA8518301A1 (es) | S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares | |
| AR012193A1 (es) | Nuevas combinaciones terapeuticas | |
| CR9155A (es) | PIRAZOLO (3,4-b) PIRIDINAS E INDAZOLES TERAPEUTICOS | |
| BR112023022514A2 (pt) | Oligonucleotídeos antissenso e seu uso para tratamento de distúrbios neurodegenerativos | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| BRPI0506631A (pt) | combinações de um agente antiemético, composição farmacêutica e usos das combinações | |
| UY28401A1 (es) | Metabolito | |
| CR9376A (es) | Agente para prevencion o tratamiento del desorden de conducta nocturna asociado con demencia | |
| PA8556101A1 (es) | 2-amino-6-(fenilo sustituido en las posiciones 2,4,5)-piridinas | |
| AR049343A1 (es) | Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos |